Cromos Pharma, where the patients are

R&D Trends

MAHSC, Roche partner

Wednesday, March 12, 2014 01:50 PM

Researchers and clinicians from Manchester Academic Health Science Center (MAHSC), a partnership involving the University of Manchester and six NHS Trusts, have launched a major partnership with global pharmaceutical company Roche. The new relationship will boost clinical research studies, which could lead to the development of new drugs and diagnostic tools and give patients in the region greater access to new treatments in development.

More... »

CRF Health eCOA webinar series

UCB, Sanofi partner for immune-mediated diseases innovation

Wednesday, March 12, 2014 01:47 PM

UCB, a global biopharmaceutical company focused on the discovery and development of medicines for the immune system and central nervous system, and Sanofi, an integrated global healthcare provider, have entered a scientific and strategic collaboration for the discovery and development of innovative anti-inflammatory small molecules, which have the potential to treat immune-mediated diseases in areas such as gastroenterology and arthritis.

More... »

Report: Drug costs projected to rise 3% to 5% in 2014

Monday, March 10, 2014 11:54 AM

Costs for medications are expected to rise 3% to 5% in all healthcare settings in 2014, according to a report published online by the American Journal of Health-System Pharmacy (AJHP), the professional journal of the American Society of Health-System Pharmacists (ASHP).

More... »

AstraZeneca, Korea Health Industry Development Institute partner

Monday, March 10, 2014 11:53 AM

AstraZeneca has signed a memorandum of understanding (MOU) with the Korea Health Industry Development Institute (KHIDI), a government-funded institution aiming to enhance global competitiveness of the healthcare industry, to establish an Oncology Research Program.

More... »

Parkinson's Disease Foundation calls on research professionals

Monday, March 10, 2014 11:51 AM

The Parkinson's Disease Foundation (PDF) invites research professionals within industry, academia and government to partner with its trained patient advocates to bring about better treatments for Parkinson's disease. This week, PDF welcomes new members to its national network, which now includes more than 230 research advocates whose insights are critical to speeding drug development.

More... »

Redx Pharma, Pierre Fabre Laboratories to collaborate on cancer research

Friday, March 7, 2014 01:11 PM

Redx, a provider of translational research capacity and experience in cancer stem cells, tumor immunology and anti-microbial resistance, and Pierre Fabre Research Institute (IRPF) have formed an agreement for cancer research. The exclusive deal will see Redx and IRPF work together on the evaluation and development of a small molecule program for an undisclosed oncology target. Following the first stage of the collaboration, IRPF will have the option to enter into exclusive negotiations to license global rights for the program in selected cancer indications.

More... »

Report: R&D sector growth fueled by diversifying innovation

Thursday, March 6, 2014 03:48 PM

CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio and a provider of exhibitions, conferences and online communities for pharmaceutical professionals, has found the R&D market is diversifying innovation in its Pharma Insights report on R&D.

More... »

Santen, Tracon ink ophthalmology agreement

Wednesday, March 5, 2014 01:21 PM

Tracon Pharmaceuticals and Santen Pharmaceutical have entered into an exclusive agreement for the development and global commercialization of Tracon's anti-endoglin antibodies, including TRC105, in ophthalmology. Preclinical and clinical data from Tracon's ongoing development of TRC105, in combination with anti-VEGF products in oncology, indicate inhibiting both the endoglin and VEGF pathways has the potential to show advantages over inhibiting VEGF alone in the treatment of conditions such as wet age-related macular degeneration (wet AMD).

More... »

Eisai, Biogen Idec collaborate on Alzheimer’s disease treatments

Wednesday, March 5, 2014 01:12 PM

Eisai, a research-based pharmaceutical company, and Biogen Idec have entered into a collaboration to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease (AD), E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idec’s candidates for AD, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

More... »

Curie-Cancer, DNA Therapeutics partner on conventional therapy-resistant cancer

Wednesday, March 5, 2014 01:09 PM

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company developing a new class of cancer drugs, are renewing their partnership. The ongoing collaboration aims to provide a new class of therapeutic cancer products to patients, including those resistant to conventional therapies.

More... »

CenterWatch Drugs in Clinical Trials



Browse by:


April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs